Following strategic reprioritization, Rocket Pharmaceuticals voluntarily withdrew its FDA biologics license application for RP-L102, a gene therapy targeting Fanconi anemia. The company cited business and pipeline considerations rather than safety or efficacy concerns. This decision follows prior regulatory setbacks and shifts focus towards cardiovascular programs in its pipeline. Rocket indicated openness to future partnerships to resume development, illustrating the challenging path for gene therapies in rare hematologic disorders.